AuntMinnie
APRIL 4, 2024
Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.
AuntMinnie
JUNE 9, 2024
Welch Award in 2012; the Distinguished Investigator Award from the Academy of Radiology Research in 2014; SNMMI's Paul C. She has co-authored more than 200 articles, focusing on developing radiopharmaceuticals for oncological imaging and therapy, the society said.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
DECEMBER 8, 2023
Suspicion of malignancy may be prompted by avid uptake of the radiopharmaceutical FDG on PET/CT imaging, according to study results delivered on November 27 at the RSNA meeting.
AuntMinnie
JUNE 20, 2024
Additionally, the tracer was found useful in 2014 in patients with PHPT. We expect these findings to contribute to the marketing authorization of this existing radiopharmaceutical for a new clinical indication,” it concluded. This study further supports its use in these patients, the team wrote. “We
Imaging Technology
JULY 9, 2024
Dr. David Gauden, a co-founder of Blue Earth Diagnostics and with the company since 2014, assumes the role of full-time CEO of Bracco subsidiary Blue Earth Therapeutics. Campione also joins the Blue Earth Diagnostics Ltd. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Board of Directors.
AuntMinnie
OCTOBER 25, 2024
Elliot Fishman, MD, Johns Hopkins Medicine The second finalist is Elliot Fishman, MD, a category for which he took the trophy in 2001, 2007, 2014, and 2017. Beyder played a key role in launching the radiopharmaceutical therapy (RPT) comprehensive center of excellence at WU, BJH, and Siteman Cancer Center last year.
Imaging Technology
JUNE 10, 2024
Anderson has been a trailblazer in the translation of novel PET agents for the imaging and targeted radiopharmaceutical therapy of cancer and other diseases,” said SNMMI President Helen Nadel , MD, FRCPC, FSNMMI. Louis , Missouri, where she worked more than 20 years developing PET and radiopharmaceutical therapy agents.
Expert insights. Personalized for you.
238 
Let's personalize your content